We've ceased enrolment & dosing in the $CHM CDH17 Phase 1 study following a second dose-limiting toxicity at Dose Level 3. Anti-tumour activity observed supports CDH17 as a valid target for further development, with a focus on an in vivo approach. app.sharelinktechnologies.co…

Our Quarterly Activities Report for the period ending 30 June 2026 has been released. View the full $CHM report: app.sharelinktechnologies.co…

We've received $1.62M advance on our FY2026 R&D tax incentive. The funding will support our ongoing Phase 1/2 clinical trial activities and general working capital as we continue our previously announced Strategic Review. app.sharelinktechnologies.co…

Investor Presentation: July 2026 View the full $CHM Presentation here: app.sharelinktechnologies.co…

Yesterday, our CEO Dr Rebecca McQualter presented at the Melbourne TechKnow 2026 Roadshow, providing an update on $CHM's clinical-stage cell therapy portfolio, including our CDH17 CAR-T Phase 1/2 trial and CORE-NK platform. We look forward to presenting in Sydney tomorrow.

We're looking forward to attending the TechKnow Invest Roadshow in Melbourne and Sydney on 27 & 29 July, where our CEO, Dr Rebecca McQualter, will present an update on Chimeric Therapeutics. Monday, 27 July 2026 2:30pm, Sydney Wednesday, 29 July 2026 9:00am, Melbourne $CHM

We've treated 4 patients at the highest dose, Dose Level 3, in our ongoing Phase 1/2 clinical trial of $CHM CDH17. New preliminary data from 2 patients shows encouraging anti-tumour activity, including tumour shrinkage of 17% to 40% in individual lesions. tinyurl.com/mum3jbfa

Our CEO Dr Rebecca McQualter will be speaking at ISCT ANZ 2026 in Melbourne as part of the Commercial Workstream session, "Capital Raising to FIH to Path to Commercialisation." Tuesday, 21 July, 4:45pm to 5:45pm. Learn more: isctglobal.org/ #ISCTANZ2026 $CHM

We're proud to announce that $CHM has been recognised with the Regional Leadership Award – CGT Company of the Year (Australia & New Zealand) at the Asia-Pacific CGT Excellence Awards 2026. Thank you to the organisers & congratulations to all of this year's finalists and winners.

This Bowel Cancer Awareness Month, we recognise the impact of bowel cancer across Australia. @Chimeric is advancing $CHM CDH17, a CAR T-cell therapy being investigated in colorectal & other gastrointestinal cancers. We're focused on developing new treatment options for patients.